Bioactive Technology

Our groundbreaking Plasma-based Bioactive Materials (PBM) are designed to improve
patient outcomes and thereby potentially reduce healthcare costs across a variety of clinical settings


Currently engaged in HEAL II pivotal study designed to show Healing Enhance & Accelerated in Long bone fracture


Currently engaged in ongoing pre-clinical studies for androgenetic alopecia

Wound Care

Currently engaged in ongoing pre-clinical studies designed to test for benefits of chronic wound healing


Our BHA product is undergoing ongoing pre-clinical studies as an orthobiologic dental bone graft substitute

Our dedicated team has a passion for making a difference in the lives of patients. We are developing multiple transformational PBM products to address unmet clinical needs.

Carmell Therapeutics' Product Pipeline
Gloved hand holding PBM putty

Our patented Plasma-based Bioactive Materials (PBMs) promote healing.

Our PBMs contain a wide array of growth factors found in platelet-enriched plasma from allogeneic sources.

A First-In-Human (FIH) clinical trial was successfully completed on the use of the Bone Healing Accelerant to treat open tibia fractures (trauma).


Clinical Data

Technician working in the lab

Accelerate Healing When It Is Needed the Most

Our proprietary process binds and crosslinks lyophilized plasma and platelet-derived proteins to extend the presence of our bioactive materials when implanted. In vivo, our PBMs break down over time via proteolysis, releasing the active biologics to accelerate healing.

Syringe containing Carmell product



Carmell Therapeutics Gains Alignment with FDA on a Path Forward to Evaluate the Use of Its Lead Product, a Bone Healing Accelerant, in Foot and Ankle Fusion Surgery

Carmell Therapeutics, a pioneer in the development and commercialization of innovative Plasma-based Bioactive Materials (PBMs) to accelerate bone and soft tissue healing, announced that it has gained alignment with U.S. Food and Drug Administration (FDA) on requirements for the evaluation of the Company’s lead product, a Bone Healing Accelerant (BHA) in a second indication, foot and ankle fusion surgery.

Read more


Carmell Therapeutics Announces the Appointment of Sebastian “Sebby” Borriello to Chief Business Officer

Carmell Therapeutics, a pioneering company in the development and commercialization of innovative Plasma-based Bioactive Materials (PBMs) to accelerate bone and soft tissue healing, today announced that Sebastian “Sebby” Borriello joined the company as Chief Business Officer.

Read more

3 overlaid images depicting various members of the Carmell team

Careers – Join An Exceptional Team

See Open Positions